Lentiviral vectors remain the go-to choice for the efficient delivery of large therapeutic genes to patient cells. In addition to ex vivo indications, the development of lentiviral vectors for in vivo applications is being re-invigorated through more specific targeting. Yet, improvements in both production scale and product quality are needed to realize this. Moreover, the architecture and features of lentiviral vectors used in the clinic have not changed significantly over the last two decades, and so their limitations, such as packaging size limit, or transgene-specific impacts on titer, may impede the success of therapeutic development, therefore increasing the need for 4th generation lentiviral vectors.
Join this webinar to learn about Oxford Biomedica’s latest lentiviral vector technology, the TetraVecta™ system, which can significantly enhance the development and manufacturing of safer and more effective lentiviral vector-based therapies. Discover how this advanced technology improves quality, potency and packaging capacity, revolutionizing the manufacturing process. These 4th generation lentiviral vectors have the potential to streamline complex manufacturing processes, enhance productivity and open possibilities for developing new treatments.
The featured speakers will review the current state of lentiviral vector engineering, recent breakthroughs, and new ways to make high-titer stable producer cell lines.
A live Q&A session will follow the presentation, offering attendees a chance to pose questions to the expert team.
Nick Clarkson, Vice President, Head of Platform Research, Oxford Biomedica
Nick Clarkson is the Vice President, Head of Platform Research at Oxford Biomedica which drives innovation of Oxford Biomedica’s core LentiVector™ platform, through vector design and improvement, generation of packaging and producer cell lines, small-scale process development, computer-aided biology and development of core analytics. The group’s mission is to keep the LentiVector® platform at the cutting edge of gene therapy and to ensure its applicability to the needs of the wider cell and gene therapy community.
Nick obtained his PhD in molecular immunology from the University of Oxford where he studied leukocyte cell surface receptor interactions and signalling pathways. After several roles in academia and industry Nick joined Oxford Biomedica in 2014, focusing on analytical development and the characterization of lentiviral vectors with a view for commercial release before becoming Head of Platform Research.
Dan Farley, Senior Director of the Vector Engineering Group, Oxford Biomedica
Dan Farley is Senior Director of the Vector Engineering Group at Oxford Biomedica. He joined the company in 2004, having completed a PhD at Warwick University working on adenoviral vectors and cell line development. The Vector Engineering Group was founded in 2013 to improve OXB’s lentiviral vector platform and technology for cell line development, which later expanded to vector-agnostic technologies, encompassing rAAVs and adenoviral vectors.
Who Should Attend?
This webinar will appeal to professionals working in:
- Cell and gene therapy programs
- Biotechnology and pharmaceutical companies
- Academics — Project Managers/Technical Experts
- Gene synthesis and plasmid companies
- Vector services cores and CDMOs
What You Will Learn
Attendees will gain insights on:
- Advances in vector engineering to enhance lentiviral vector production
- Impact of transgene’s cytotoxicity and RNA splicing on viral vector titre and quality
- Solutions for developing high-titre stable producer cell lines
- Considerations when embarking on LV gene therapy to maximise success
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US.